Article

Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura.

Servicio de Hematología, Hospital Clínico Universitario y Centro de Investigación del Cáncer de Salamanca, Spain.
Cytotherapy (impact factor: 3.63). 01/2009; 11(6):698-705. DOI:10.3109/14653240903051558 pp.698-705
Source: PubMed

ABSTRACT Immune thrombocytopenic purpura (ITP) is a bleeding disorder characterized by an accelerated destruction of platelets as a result of the presence of autoreactive antibodies. Patients with ITP also display activated platelet-autoreactive T cells. Mesenchymal stem cells (MSC) inhibit both T- and B-cell activation and may have functional impairments in autoimmune disorders.
We analyzed the potential role of MSC in the pathogenesis of ITP.
MSC from ITP showed an impaired proliferative capacity and a lower capability of inhibiting activated T-cell proliferation compared with healthy donors. While MSC from controls showed a decreased expression of p27 after stimulation with platelet-derived growth factor, this effect was not observed in MSC from patients. Furthermore, MSC from healthy donors down-regulated p16 upon exposure to platelet-released supernatant, while this effect was not observed for ITP. Interestingly, caspase 9 expression was higher in MSC from ITP.
These abnormalities suggest a role of MSC malfunction in the physiopathology of the disease and may have therapeutic implications.

0 0
 · 
0 Bookmarks
 · 
30 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

accelerated destruction
 
autoimmune disorders
 
autoreactive antibodies
 
bleeding disorder
 
caspase 9 expression
 
decreased expression
 
healthy donors down-regulated p16
 
Immune thrombocytopenic purpura
 
impaired proliferative capacity
 
inhibiting activated T-cell proliferation
 
Interestingly
 
ITP
 
lower capability
 
MSC
 
MSC malfunction
 
Patients
 
platelet-derived growth factor
 
platelet-released supernatant
 
platelets
 
potential role
 

Jose Antonio Pérez-Simón